News - Research, Biogen Idec

Filter

Current filters:

ResearchBiogen Idec

Popular Filters

1 to 25 of 38 results

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30-05-2014

US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

AAN 2014: Biogen Idec releases new trial data for peginterferon in MS

AAN 2014: Biogen Idec releases new trial data for peginterferon in MS

02-05-2014

US biotech firm Biogen Idec has released new two-year data from the Phase III ADVANCE clinical trial…

Biogen IdecBiotechnologyCytokinesHealth Medical PharmaHealth Medical PharmaImmune systemImmunologyNeurologicalpeginterferon beta-1aResearchUSA

Biogen Idec 1st-qtr 2014 revenue leaps 51%, driven by Tecfidera and MS franchise

23-04-2014

US biotech firm Biogen Idec first-quarter 2014 results today, including revenue of $2.1 billion, a 51%…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTecfidera

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

Positive Ph III pediatric data for investigational hemophilia A drug Eloctate

Positive Ph III pediatric data for investigational hemophilia A drug Eloctate

10-04-2014

US biotech firm Biogen Idec and Swedish Orphan Biovitrum today released positive top-line results of…

Biogen IdecEloctateHematologyResearchSwedish Orphan Biovitrum

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

10-01-2014

US biotech firm Biogen Idec and Sangamo Biosciences have signed an exclusive worldwide collaboration…

Biogen IdecBiotechnologyHematologyLicensingResearchSangamo BioSciences

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

10-12-2013

This year’s American Society of Hematology (ASH) meeting continued yesterday with more clinical trial…

Biogen IdecEloctateHematologyJakaviNovartisPharmaceuticalResearchSobiTakeda PharmaceuticalsUSA

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

Proteostasis Therapeutics in neurodegenerative disease deal with Biogen Idec

10-12-2013

US drug developer Proteostasis Therapeutics has entered into a worldwide collaboration with biotech major…

Biogen IdecBiotechnologyLicensingNeurologicalProteostasis TherapeuticsResearch

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

Biogen and SOBI announce top line results for hemophilia A treatment Eloctate

14-11-2013

US biotech major Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) have announced detailed…

Biogen IdecBiotechnologyEloctateHematologyNorth AmericaResearchSobiUSA

Galapagos in deal with Biogen Idec for scleroderma research

Galapagos in deal with Biogen Idec for scleroderma research

13-11-2013

Belgian biotech firm Galapagos says that a subsidiary has signed a three-year collaboration agreement…

Biogen IdecBiotechnologyDermatologicalsGalapagosLicensingResearch

Isis Pharma earns $10 million milestone in deal with Biogen

16-10-2013

Isis Pharmaceuticals says that it has earned a $10 million milestone payment from fellow USA-based biotech…

Biogen IdecBiotechnologyFinancialIsis PharmaceuticalsISIS-DMPKrxRare diseasesResearch

Biogen Idec presents new Tecfidera data in MS at ECTRIMS

04-10-2013

Biogen Idec presented data showing that Tecfidera continues to offer consistent and strong efficacy combined…

Biogen IdecBiotechnologyNeurologicalResearchTecfidera

Biogen Idec in deal with Amicus for Parkinson's disease

11-09-2013

US biotech firm Amicus Therapeutics (Nasdaq: FOLD) has entered a collaboration with Biogen Idec (Nasdaq:…

Amicus TherapeuticsBiogen IdecBiotechnologyLicensingNeurologicalResearch

Biogen Idec and Isis Pharma collaborate in $100 million upfront deal

10-09-2013

US biotech firms Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

Alkermes reveals candidates for MS, cancer and pain

18-07-2013

US drugmaker Alkermes (Nasdaq: ALKS) has unveiled three new drug candidates for the treatment of multiple…

AlkermesBiogen IdecNeurologicalNorth AmericaOncologyPharmaceuticalResearchTecfidera

New data supports safety of Biogen and SOBI's Eloctate for hemophilia A

05-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) and Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) have…

AlprolixBiogen IdecEloctatePharmaceuticalResearchSobi

New data support safety and efficacy of Biogen Idec and SOBI's Alprolix

03-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) yesterday presented…

AlprolixBiogen IdecBiotechnologyPharmaceuticalResearchSwedish Orphan Biovitrum

Biogen Idec's Plegridy reduces MS relapse rate by 36%

20-03-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) released strong new first full-year results from its two-year…

Biogen IdecBiotechnologyNeurologicalpeginterferon beta-1aPlegridyResearch

Merck & Co in biosimilars deal with Samsung Bioepis

21-02-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into an agreement with South Korea-based Samsung Bioepis…

Biogen IdecBiotechnologyMerck & CoPharmaceuticalProductionResearchSamsung Bioepis

Biogen Idec to drop ALS drug after failure in Ph III trial

04-01-2013

Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell as much as 8% to $138.05 in pre-market trading…

Biogen IdecBiotechnologydexpramipexoleNeurologicalResearch

Biogen Idec and Isis Pharma in up to $230 million antisense deal

11-12-2012

USA-based companies Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

News briefs from Sanofi, Biogen/SOBI and Novartis

01-11-2012

French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

1 to 25 of 38 results

Back to top